Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Giotrif Afatinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse Complete
Givlaari givosiran Acute hepatic porphyria (AHP) in adults Reimburse with clinical criteria and/or conditions Complete
Glatect Glatiramer acetate Relapsing Remitting Multiple Sclerosis (RRMS) Reimburse with clinical criteria and/or conditions Complete
Grastek Phleum pratense Allergic rhinitis Do not list Complete
Grastofil Filgrastim Neutropenia List with clinical criteria and/or conditions Complete
Gynazole.1 Butoconazole nitrate Vaginal infection Do not list Complete
Halaven Eribulin Mesylate Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Harvoni ledipasvir, sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Harvoni Ledipasvir / Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete
Hemangiol Propranolol Infantile hemangioma Withdrawn